Randomized, Double-blinded, Placebo-controlled Phase II Study of Vandetanib (ZactimaTM) Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2016
At a glance
- Drugs Vandetanib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- Sponsors AstraZeneca
- 13 Oct 2016 Genzyme and AstraZeneca entered into an agreement after the trial was completed, hence I have not added Genzyme in the association field.
- 16 Apr 2012 Actual end date Dec 2011 added as reported by ClinicalTrials.gov.
- 06 Aug 2011 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History